GeneMedi's GPCR portfolio for GPCR targeting drug discovery and mechanism of action (MOA) research.

GeneMedi's GPCR portfolio offers a comprehensive range of ligands, agonists and antagonists that are highly selective in their target binding and are therefore ideally suited for target validation and drug discovery projects. G protein-coupled receptors (GPCRs) are transmembrane proteins that regulate a wide range of physiological processes including neurotransmission, hormone signaling, and immune responses. They represent the largest family of membrane receptors in humans and are a major target for drug development in the pharmaceutical industry. GPCRs are classified into five families based on their phylogenetic relationship, including the rhodopsin-like, secretin-like, metabotropic glutamate, fungal pheromone, and cAMP receptor families. Each family of GPCR comprises several important proteins that have distinct functions and therapeutic applications.

For instance, the rhodopsin-like family of GPCRs includes adrenergic, dopamine and serotonin receptors that play critical roles in cardiovascular function, mood disorders, and sleep-wake cycle, respectively. The secretin-like family of GPCRs includes vasopressin, opioid, and calcitonin receptors that play essential roles in fluid balance, pain modulation, and calcium homeostasis, respectively. The targeting of specific GPCRs and their associated signaling pathways has led to several diagnostic and therapeutic applications. GPCRs are involved in the pathogenesis of many diseases, including cancer, diabetes and cardiovascular diseases, and, therefore, offer attractive targets for drug development. Several drugs, such as beta-blockers, angiotensin receptor blockers, and anti-histamines, target GPCRs and have been approved for the treatment of various diseases. In addition, the detection of certain GPCRs can be used as diagnostic markers for some diseases. For example, overexpressed GPCRs have been linked to cancer development and progression, and their detection can be used for the early diagnosis and prognosis of the disease.

GPCRs represent an attractive and diverse class of therapeutic targets with significant potential in drug discovery and development. Their complex signaling pathways and functions create numerous opportunities for precision medicine and personalized therapies. GeneMedi offers benchmark antibodies that cover various research applications for GPCR, including ELISA, affinity binding assays, drug discovery, and mechanism of action (MOA) research. Our pre-made monoclonal antibodies are expressed using mammalian cell lines that ensure high quality and reproducibility, making them ideal for use as therapeutic reference antibodies for applications such as cell culture, assay development, animal model development, and PK/PD model development for biological drug discovery.

Q&A

Q1. What is GeneMedi's GPCR portfolio?
A1: GeneMedi's GPCR portfolio offers a comprehensive range of ligands, agonists, and antagonists that are highly selective in their target binding and are ideal for drug discovery and target validation.

Q2. What are GPCRs?
A2: GPCRs are transmembrane proteins that regulate various physiological processes like hormone signaling, neurotransmission, and immune responses. They represent the largest family of membrane receptors in humans.

Q3. How are GPCRs classified?
A3: GPCRs are classified into five families based on their phylogenetic relationships, namely rhodopsin-like, secretin-like, metabotropic glutamate, fungal pheromone, and cAMP receptor families.

Q4. What therapeutic applications do GPCRs have?
A4: GPCRs have several therapeutic applications such as cardiovascular function regulation, pain modulation, fluid balance regulation, and calcium homeostasis. They are also involved in diseases such as cancer, diabetes, and cardiovascular diseases and offer attractive targets for drug development.

Q5. What products does GeneMedi offer for GPCR research?
A5: GeneMedi provides benchmark antibodies for various research applications for GPCR, including ELISA, affinity binding assays, drug discovery, and mechanism of action research.